262 related articles for article (PubMed ID: 28626166)
1. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
[TBL] [Abstract][Full Text] [Related]
2. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis-Case Series.
Kobayashi T; Nakamura Y; Suzuki T; Yamaguchi T; Takeda R; Takagi M; Hasegawa T; Kosho T; Kato H
J Clin Med; 2018 Nov; 7(12):. PubMed ID: 30477250
[TBL] [Abstract][Full Text] [Related]
6. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
7. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
8. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
[TBL] [Abstract][Full Text] [Related]
10. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
11. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
Hoyer-Kuhn H; Franklin J; Allo G; Kron M; Netzer C; Eysel P; Hero B; Schoenau E; Semler O
J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):24-32. PubMed ID: 26944820
[TBL] [Abstract][Full Text] [Related]
13. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
14. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
17. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
18. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
[TBL] [Abstract][Full Text] [Related]
19. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
20. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Haschka J; Hans D; Nia A; Geroldinger A; Ardelt M; Wakolbinger R; Resch H
Osteoporos Int; 2015 Oct; 26(10):2431-40. PubMed ID: 25956285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
